BrainIAC, a new foundation model from Mass General Brigham, outperforms traditional AI approaches in analyzing brain MRI for tasks like brain age estimation and cancer prognosis.
Key Details
- 1BrainIAC was pretrained on nearly 49,000 brain MRI scans using self-supervised learning.
- 2Validated across seven diverse clinical MRI tasks, including brain age, dementia risk, tumor mutation detection, and survival prediction.
- 3Outperformed three conventional, task-specific AI models, especially in scenarios with limited labeled data.
- 4Demonstrated strong generalizability across healthy and diseased cases as well as different MRI types.
- 5Study published in Nature Neuroscience, developed by Mass General Brigham, and funded by NIH/NCI among others.
Why It Matters
This work introduces a flexible, generalizable AI tool that could streamline the adoption of imaging AI in clinical practice, particularly where annotated data is limited. BrainIAC's ability to perform well across a range of complex imaging tasks may help accelerate personalized medicine and clinical decision making in neuroradiology.
Source
EurekAlert
Related News
•EurekAlert
NIH-Backed AI Model Predicts Cancer Survival Using Single-Cell Data
Researchers have developed scSurvival, a machine learning tool that uses single-cell tumor data to accurately predict cancer patient survival and identify high-risk cell populations.
•EurekAlert
Deep Learning Pathomics Platform Improves Immunotherapy Prediction in Lung Cancer
A deep learning pathomics platform accurately predicts immunotherapy response in metastatic NSCLC using routine pathology slides.
•EurekAlert
AI Pathology Model Outperforms PD-L1 in Predicting NSCLC Immunotherapy Response
MD Anderson's Path-IO machine learning platform accurately predicts immunotherapy responses in metastatic non-small cell lung cancer, surpassing current biomarker standards.